GMP manufacturing begins as Ebola outbreak claims nearly 4,000 lives
The Bundibugyo Ebola outbreak has recorded 8,137 confirmed cases and 3,926 confirmed deaths as of 27 September 2026, representing a confirmed case fatality ratio of approximately 48%. Against this backdrop, GMP manufacture of Galidesivir active pharmaceutical ingredient (API) commenced on 1 October 2026 at PI Health Sciences (PIHS), marking a material execution milestone for Island Pharmaceuticals (ASX: ILA).
There is currently no approved specific treatment for Bundibugyo Ebola virus disease, underscoring the urgent need for additional medical countermeasures. Island Pharmaceuticals is an Australian antiviral drug development and biodefence company advancing Galidesivir as a broad-spectrum antiviral candidate for high-consequence viral threats.
When big ASX news breaks, our subscribers know first
Two manufacturing campaigns, two strategic objectives
The manufacturing program is structured around two distinct 5kg GMP API batches, each serving a separate strategic purpose.
- Batch 1: Targeted for completion by the end of October 2026, this batch has been earmarked for Island’s approved emergency-use MEURI program in Uganda during the current Bundibugyo Ebola outbreak. Following API manufacture, finishing, vialing and packaging activities will be undertaken ahead of planned shipment.
- Batch 2: Targeted for completion by late November 2026, this batch is intended to support Island’s broader Ebola strategy and its planned pivotal Marburg non-human primate (NHP) study under the FDA Animal Rule pathway.
The broader manufacturing program also encompasses analytical method validation, reference standard preparation and stability studies, establishing the GMP quality framework required to support future regulatory and government procurement activities. Manufacturing is being undertaken at PIHS under Island’s existing agreement with the facility (refer ASX announcement: 4 June 2026).
What is the MEURI framework and why does it matter for investors?
MEURI stands for the World Health Organization’s Monitored Emergency Use of Unregistered and Investigational Interventions framework. It is a mechanism that allows investigational drugs to be used in emergency outbreak settings before full regulatory approval has been obtained.
Galidesivir has already received authorisation for investigational therapeutic use under the MEURI framework for the current Bundibugyo outbreak. Critically for investors, treatment under MEURI occurs under a prospective protocol, meaning clinical, safety and virological data will be collected from patients treated with Galidesivir in real time.
This is not solely a humanitarian deployment. The data generated under this framework has the potential to add an important human evidence stream to the substantial body of preclinical and clinical data already established for the drug, potentially strengthening the broader development case for Galidesivir beyond the current outbreak.
Building on US$70M in prior US Government investment
Galidesivir enters this program with a well-established development foundation. The broad-spectrum antiviral has benefited from more than US$70 million in prior US Government investment, alongside existing human clinical experience and historical efficacy data in NHP models of both Ebola and Marburg virus disease.
Island is now pursuing two complementary evidence-generation pathways to build on that base:
- Prospective human data collection in Ebola under the MEURI framework
- Controlled Marburg NHP studies supporting the FDA Animal Rule pathway
The FDA Animal Rule is a regulatory pathway that allows drugs targeting serious or life-threatening conditions to be approved on the basis of animal efficacy data when human trials are not ethical or feasible. This pathway is directly relevant to investors assessing the regulatory route for Island’s Marburg program.
The FDA Animal Rule pathway was validated for Galidesivir earlier in 2026 when Island secured FDA alignment on the Marburg animal model, locking in the study parameters before the efficacy phase and removing the primary regulatory uncertainty that had previously overhung the program.
The GMP manufacturing program strengthens Galidesivir’s deployment readiness and positions the asset for potential future government procurement and biodefence opportunities.
For investors exploring the commercial and procurement context behind Galidesivir’s development, our full explainer on Island’s US biodefence network strategy covers the MC2 working group memberships and the Strategic National Stockpile positioning effort that frames the government procurement upside referenced in Island’s manufacturing rationale.
CEO and Managing Director, Dr David Foster
“The commencement of physical GMP manufacture is an important execution milestone for Galidesivir. The first 5kg campaign is now underway and our immediate objective is to establish GMP supply that can support the approved MEURI program while the Bundibugyo Ebola outbreak remains active.
“Importantly, treatment under the MEURI framework will occur under a prospective protocol, creating the opportunity to collect clinical, safety and virological data from patients treated with Galidesivir. This has the potential to add an important human evidence stream to the substantial body of preclinical and clinical data already established for the drug.
“In parallel, the second 5kg manufacturing campaign is intended to support our broader Ebola strategy and planned pivotal Marburg NHP study. These are complementary development pathways intended to advance Galidesivir, pursuing potential real-world treatment experience in Ebola while progressing the defined Animal Rule pathway in Marburg.
“Together, these activities strengthen Galidesivir’s development readiness as we work to position it as a potential broad-spectrum medical countermeasure for high-consequence viral threats.”
Key milestones to watch
Investors should monitor the following near-term milestones across Island’s Galidesivir manufacturing program:
- End of October 2026 — Batch 1 (5kg GMP API) targeted for completion
- Post-Batch 1 — Finishing, vialing and packaging activities, followed by planned shipment to Uganda
- Late November 2026 — Batch 2 (5kg GMP API) targeted for completion
- Post-Batch 2 — Material to support broader Ebola strategy and pivotal Marburg NHP study
| Batch | Volume | Target Completion | Purpose | Regulatory Framework |
|---|---|---|---|---|
| Batch 1 | 5kg GMP API | End of October 2026 | Emergency-use MEURI program in Uganda (Bundibugyo Ebola outbreak) | WHO MEURI |
| Batch 2 | 5kg GMP API | Late November 2026 | Broader Ebola strategy and pivotal Marburg NHP study supply | FDA Animal Rule |
Island is advancing a dual asset strategy alongside the Galidesivir biodefence and outbreak program. Its second asset, ISLA-101, is being developed for the prevention and treatment of dengue fever and other vector-borne diseases, providing a complementary development pathway targeting a distinct viral disease area.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.